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Background: Aortobronchial fistula (ABF) and aortoesophageal fistula (AEF) are rare but lethal if untreated; open
thoracic surgery is associated with high operative mortality and morbidity. In this case series, we sought to investigate
outcomes of thoracic endovascular aortic repair (TEVAR) for emergency cases of ABF and AEF.
Methods: We retrospectively reviewed all patients with AEF and ABF undergoing TEVAR in three European teaching
hospitals between 2000 and January 2009. Eleven patients were identified including 6 patients with ABF, 4 patients with
AEF, and 1 patient with a combined ABF and AEF. In-hospital outcomes and follow-up after TEVAR were evaluated.
Results: Median age was 63 years (interquartile range, 31); 8 were male. Ten patients presented with hemoptysis or
hematemesis; 4 developed hemorrhagic shock. All patients underwent immediate TEVAR, and 3 AEF patients required
additional esophageal surgery. Five patients died (45%), including 3 patients with AEF, 1 patient with ABF, and 1 patient
with a combined ABF and AEF, after a median duration of 22 days (interquartile range, 51 days). The patient with AEF
that survived had received early esophageal reconstruction. Causes of death were: sepsis (n 2), acute respiratory distress
syndrome (ARDS) (n 1), thoracic infections (n 1), and aortic rupture (n 1).Median follow-up of surviving patients
was 45 months (interquartile range, 45 months). Six additional vascular interventions were performed in 3 survivors.
Conclusion: TEVAR does prevent immediate exsanguination in patients admitted with AEF and ABF, but after initial
deployment of the endograft and control of the hemodynamic status, most patients, in particular those with AEF, are at
risk for infectious complications. Early esophageal repair after TEVAR appears to improve the survival in case of AEF.
Therefore, TEVARmay serve as a bridge to surgery in emergency cases of AEF with subsequent definitive open operative
repair of the esophageal defect as soon as possible. In patients with ABF, additional open surgery may not be necessary
after the endovascular procedure. (J Vasc Surg 2009;50:999-1005.)Fistulas between the thoracic aorta and the esophagus
or lungs are rare. Aortobronchial fistula (ABF) and aortoe-
sophageal fistula (AEF) usually arise in thoracic aortic dis-
ease such as aneurysms or after previous thoracic aortic
surgery.1-5 ABF has been reported in patients with pulmonary
diseases like tuberculosis and intrapulmonary Aspergillus ab-
scess, or after bronchial stenting or previous lobectomy.6-8
AEF has been associated with esophageal carcinoma, inges-
tion of foreign bodies, and even iatrogenic esophageal
perforation or Barrett’s esophagus.9-12 Both ABF and AEF
often present with acute hemoptysis or hematemesis. Due
to the excessive bleeding, ABF and AEF are lethal if un-
treated, although open thoracic aortic repair of ABF and
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doi:10.1016/j.jvs.2009.04.043AEF is associated with high mortality and morbidity in this
critically-ill population.1-5,13 Thoracic endovascular aortic
repair (TEVAR) has shown to be an effective method for
treatment of thoracic aortic disease.14-16 TEVAR is less
invasive than open thoracic aortic surgery and is associated
with decreased operative duration. Since the introduction
of TEVAR, several cases of successful endovascular man-
agement of ABF and AEF have been reported.6,7,9-11,17
However, it is unclear if these promising reports were
exceptional cases. Furthermore, several reported cases were
performed in subacute settings instead of emergencies, and
long-term outcomes are oftenmissing. If patients with ABF
or AEF are treated with TEVAR alone, the esophageal or
bronchial defect is not repaired. Lung tissue and the esoph-
agus are non-sterile cavities in which risks of graft infections
after endovascular treatment for fistulas are likely to be
permanently increased, which is crucial when considering
long-term outcomes. In this series, we evaluated the in-
hospital and follow-up outcomes of emergency cases of
ABF and AEF treated with TEVAR, to assess the applica-
bility of endovascular therapy for these rare entities.
METHODS
We retrospectively reviewed all patients with AEF and
ABF undergoing TEVAR in Policlinico San Donato
IRCCS, Milan, Italy, the University Medical Center Utre-
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cated in The Netherlands. Approval of the human ethics
committee was obtained in all institutions. Between the
year 2000 and January 2009, 11 cases treated with TEVAR
were identified, including 6 patients with ABF, 4 patients
with AEF, and 1 patient with a combined ABF and AEF.
Median age of patients was 63 years (range, 30 to 77
years; interquartile range 31 years); 8 were male (73%).
Causes of fistula were: previous open thoracic aortic surgery
with implantation of Dacron prosthesis (n  4), thoracic
aortic aneurysm (TAA) (n 3), previous TEVAR (n 2),
ingestion of a chicken bone (n  1), and infection of a
Dacron graft of the thoracic aorta since 2 months, which
was treated by intravenous antibiotic therapy (n  1). All
patients showed an acute presentation of symptoms. Ten
patients suffered from progressive hemoptysis and/or he-
matemesis; 4 patients developed hemorrhagic shock due to
excessive bleeding. Hemorrhagic shock was present in 3
out of 4 patients with AEF. The Classification of Hemor-
rhage from the American College of Surgeons18 was used
to assess if patients were in hemorrhagic shock on admis-
sion. Patients with blood loss 1500 mL, a pulse rate
120 beats/minute, respiratory rate30 breaths/minute,
and a decreased blood pressure were classified as admitted
in hemorrhagic shock (hemorrhage class III or class IV). If
these admission data were not available retrospectively, pa-
tients were only classified as “admitted in shock” if the physi-
cian had reported this explicitly. All patients that suffered from
hemorrhagic shock received vasopressors to increase the
blood pressure. In 3 other patients, bacteremia was diagnosed
Table I. Characteristics of 11 patients undergoing TEVAR
Gender/age Fistula type Medical history
1. M/46 ABF Bentall procedure  CABG in 2001, a
arch replacement in 2002
2. F/63 ABF Bentall procedure in 1996, aortic graft
TAA in 2003
3. M/30 ABF Repair of aortic coarctation in 1977
4. M/60 ABF Aortic graft for type A aortic dissection
2003, aortic graft for TAA  PTCA
CVA in 2004
5. M/77 ABF COPD, CAD, CRI, HT
6. M/68 ABF Type B dissection in 1985, aortic graft
TAA in March 2008, aortic graft
infection in August 2008
7. M/65 AEF TEVAR for TAA in 2007, HT
8. F/40 AEF Aortic graft for type A aortic dissection
2007, 2x open repair of AEF in 200
9. F/71 AEF COPD, HT
10. M/31 AEF
11. M/75 ABF  AEF TEVAR for TAA 3 months ago, COP
CRI, HT
ABF, Aortobronchial fistula; AEF, aortoesophageal fistula; TP, thoracic pain
obstructive pulmonary disease; CAD, coronary artery disease; CRI, chronic
thoracic endovascular aortic repair; CABG, aorto-coronary bypass graft; PT
*This patient was admitted with an infected Dacron prosthesis of the thora
development of acute hemoptysis.by blood cultures. One of these patients suffered from aninfected Dacron prosthesis of the thoracic aorta, which was
treated with ceftriaxon 2 g/day. After 2 months, the patient
developed massive hemoptysis and bronchoscopy revealed
ABF, which was treated by TEVAR. The other patient was
admitted with acute hemoptysis, thoracic pain, dyspnea, and
fever. Computed tomography angiography (CTA) scan diag-
nosed ABF, which was treated with TEVAR. Blood cul-
tures turned out positive and the patient received Augmen-
tin (GlaxoSmithKline, Brentwood,Middlesex,UK) 4dd1200
mg during 3 months. In both patients, there was no evidence
of septic shock when TEVARwas offered and no vasopressors
were needed. Cause and presentation of the fistula for the 11
patients are depicted in Table I.
Ten fistulas were diagnosed using CTA scan; diagnosis
was made using bronchoscopy in 1 patient with ABF.
TEVAR was preferred over open thoracic aortic surgery at
these institutions because of emergency. Operations were
performed under general anesthesia. The endovascular de-
vice was inserted through the common femoral artery in all
cases; the angiographic catheter was positioned into the
thoracic aorta via a guidewire from the right brachial artery
in 3 patients. Patients were treated with the following
endografts: Gore TAG (W.L. Gore & Associates, Flagstaff,
Ariz) (n  4), Medtronic Talent (Medtronic Vascular, Santa
Rosa, Calif) (n  3), Medtronic Valiant (n  3) and Gore
Thoracic Excluder (n  1). Details regarding diameter, total
length, and number of endografts used during the initial
endovascular procedure are depicted in Table II. All patients
received perioperative antibiotics intravenously. Surviving pa-
tients received oral antibiotics after discharge; duration of
ABF and AEF
Fistula cause Symptoms Shock/infection
Previous aortic surgery HMP, TP, DP, F N/Y
Previous aortic surgery HMP, TP Y/N
TAA (64 mm) HMP, DP N/N
Previous aortic surgery HMP, TP N/N
Ruptured TAA HMP, TP, DP N/N
Aortic graft infection* HMP N/Y
Previous TEVAR TP N/N
Previous aortic surgery HMT Y/N
Ruptured TAA (65
mm)
HMT, TP, DP Y/N
Ingestion chicken
bone
HMT, TP, dysphagia Y/N
Previous TEVAR HMP, HMT, TP, DP N/N
P, hemoptysis; HMT, hematemesis; DP, dyspnea; F, fever; COPD, chronic
insufficiency; HT, hypertension; TAA, thoracic aortic aneurysm; TEVAR,
ercutaneous coronary angioplasty; CVA, cardiovascular accident.











CA, pantibiotic therapy ranged from 4 weeks to 3 months.
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exclusion of the fistula during initial TEVAR, complica-
tions, additional open surgery, vascular re-interventions,
mortality, hospital length of stay, and long-term follow-up.
Mortality after TEVAR was compared between ABF and
AEF using the Fisher’s exact test; the survival after TEVAR
was demonstrated using Kaplan Meier life table analysis
(SPSS version 15.0, SPSS Inc, Chicago, Ill).
RESULTS
Complete exclusion of the fistula was successfully
achieved during initial TEVAR in 9 patients (82%). In the
remaining 2 patients, a second endograft was successfully
placed in 1 patient after 2 days because of considerable
type 1 endoleak, and the last patient died after 2 days due
to aortic rupture, which was probably caused by en-
doleak type 1. The left subclavian artery was covered
during the endovascular procedures in 6 patients (54%).
Median hospital length of stay was 15 days (range, 2 days
to 89 days; interquartile range, 15 days).
Additional thoracic surgery. Additional open tho-
racic surgery was performed in 3 patients with AEF. A
31-year-old male (patient 10) suffered from AEF after
ingestion of a chicken bone 8 days earlier. He required neck
exploration 1 day after TEVAR to evacuate a large amount
of blood and a clot that had caused respiratory insufficiency.
A few days later, abdominal esophagectomy with gastric
tube reconstruction was performed. Another patient, a
71-year-old female in whom the AEF was caused by a
ruptured TAA, received bipolar esophageal exclusion in-
Table II. Characteristics of the initial endovascular proced





1. CFA  BA Excluder, 34  200 1 2/Y
2. CFA TAG, 28  150 1 4/N
3. CFA  BA Talent, 32  150 2 2/Y
4. CFA Talent, 38  100 1 2/Y
5. CFA TAG, 37  200 1 3/N
6. CFA Valiant, 36  110 1 2/Y
7. CFA  BA Valiant, 42  150 1 3/N
8. CFA Valiant, 30  150 1 3/N
9. CFA TAG, 27  150 1 4/N
10. CFA TAG, 28  100 1 2/Y
11. CFA Talent, 42  110 1 2/Y
Graft details describe the mean diameter of the endograft in mm and the tota
antibiotics (IV); surviving patients were prescribed oral antibiotics. PLZ, Pro
BA, brachial artery.
*This patient already received antibiotic therapy prior to thoracic endovascul
aorta.cluding cervical esophagostomy and jejunostomy 18 daysafter TEVAR (patient 9). The last patient who received
additional open surgery was a 65-year-old male in whom
AEF was caused by previous TEVAR (patient 7). He had
undergone successful TEVAR for AEF, but 1 week after
discharge he was readmitted with mediastinitis, which was
treated by drainage of the mediastinum and aneurysm sac,
followed by esophageal exclusion and jejunostomy.
Mortality. Four patients died during hospitalization
and 1 patient died shortly after discharge (45%). Median
time interval until death was 22 days (range, 2 to 89 days;
interquartile range, 51 days). The Fig depicts the survival
after TEVAR for ABF and AEF; no patients died during the
initial endovascular procedure. Two out of 4 patients who
were admitted with hypovolemic shock eventually expired
after 7 and 89 days due to infectious complications (pa-
tients 8 and 9). Death occurred in 3 patients with AEF, 1
patient with ABF and 1 patient with combined ABF and
AEF, Fisher’s exact test: P  .133.
The patient with the combined ABF and AEF died
from delayed aortic rupture 2 days after TEVAR (patient
11). A 40-year-old female was admitted with hypovolemic
shock after recurrent AEF and showed recurrent hemopty-
sis after TEVAR, followed by development of mediastinitis
and sepsis. She died 1 week after TEVAR (patient 8).
Another patient who had developed ABF after a ruptured
TAA showed type 1 endoleak after 2 days, requiring place-
ment of an additional endograft (patient 5). After the
re-intervention, the patient developed renal failure and
acute respiratory distress syndrome (ARDS), which re-





— Augmentin 4dd1200 mg,
3 months
— Amoxicillin 3dd500 mg,
10 weeks
— Augmentin 3dd 625 mg,
until death
— Cefuroxim 2dd 500 mg,
3 months
— Not applicable
— Ceftriaxon 2 g/d IV*
sophageal exclusion, drainage





sophageal exclusion after 18 days Not applicable
eck exploration after 1 day,
esophagectomy and gastric tube
after 4 days
Augmentin 3dd 625 mg,
3 months
— Not applicable
th of the endograft(s) in mm. All patients received perioperative intravenous
landing zone; left SCA, left subclavian artery;CFA, common femoral artery;
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patient who died was the 71-year-old female who had received
bipolar esophageal exclusion for AEF. She suffered from aortic
rupture at the proximal endograft neck, which was treated with
placement of a second endograft. The patient developed respira-
tory failure due to severe thoracic infections, resulting in death
after an intensive care unit (ICU) stay of almost 3 months.
The patient with AEF who received early esophageal
repair a few days after TEVAR was the only patient with
AEF who did not expire (patient 10).
Follow-up. Median follow-up of surviving patients
was 45months (range, 3 to 61months; interquartile range,
45 months). Six additional vascular interventions were
performed in 3 survivors during this period.
A left-sided carotid subclavianbypasswas performedprior to
TEVAR to extend the proximal landing zone in a 68-year-old
male with ABF after an infected aortic graft prior to TEVAR.
Postoperatively the patient suffered from Horner’s syndrome
due to damage of the sympathic nerve fibers (patient 6).
The patient with AEF after ingestion of a chicken bone
needed a repeat TEVAR 1 day after the initial procedure.
The manipulation during the open surgical procedure re-
sulted in severe bleeding that necessitated deploying of a
longer endograft inside the first one. Nine months after
discharge, he presented with thrombosis of both popliteal
arteries, which was treated with embolectomy. CTA scan
showed infolding of the second endograft, and a giant
Palmaz stent (Cordis, Miami Lakes, Fla) was placed in the
second endograft with resolution of the complication.
The other survivor who required re-interventions was a
30-year-old male (patient 3) who had developed TAA with
concomitant ABF after open repair of an aortic coarctation.
During TEVAR, the ABF was excluded but coverage of the





1. Y 7 —
2. Y 15 —
3. Y 22 Endoleak type 1, brachial claudication
4. Y 8 Brachial claudication
5. N 22 Endoleak type 1, renal failure, ARDS
6. Y 60* Horner syndrome
7. Y 7 Mediastinitis
8. Y 7 Recurrence hemoptysis, mediastinitis
9. Y 89 Aortic rupture at proximal endograft
neck, thoracic infections
10. Y 19 Bleeding after 24 hours, infolding of
inner endograft
11. N 2 Aortic rupture
Successful was defined as complete exclusion of the fistula during initial thor
SCA, subclavian artery; ABF, aortobronchial fistula; AEF, aortoesophageal
*This patient was already hospitalized for 2 months because of an infectedleft subclavian artery was necessary in order to have a safeproximal landing zone. Endovascular ballooning was per-
formed 3 days after the first endovascular procedure be-
cause of a type 1 endoleak, with immediate good results.
After discharge, the patient suffered from brachial claudi-
cation, which was treated successfully with transposition of
the left subclavian artery. The other 3 survivors did not
require re-intervention, although 1 suffered from mild
brachial claudication due to coverage of the left subclavian
artery during initial TEVAR. Outcomes of TEVAR are
depicted in Table III.
DISCUSSION
In this case series, TEVAR prevented immediate exsan-
guination caused by ABF or AEF; no patients died during the
initial endovascular procedure. However, 5 out of 11 patients
with ABF or AEF died of complications between 2 days and 3
months after the initial endovascular procedure (Fig).
Aortobronchial and aortoesophageal fistulas are scarce
and usually arise in thoracic aortic disease or after previous
thoracic aortic repair. ABF and AEF regularly present with
excessive bleeding; repair of the fistula is the only curative
treatment.1-5 Adequate management of ABF or AEF con-
sists of control of hemorrhage, repair of the bronchial or
esophageal defect, control of infectious complications, and
maintenance of sufficient distal perfusion.
Traditional surgical repair of ABF usually occurs by a
posterolateral thoracotomy, followed by resection of the
involved aortic area of the fistula and replacement of this
part by a prosthetic graft. Bronchial or lung surgical repair
may consist of primary closure or partial resection of lung
tissue. The bronchial segment of the fistula has been treated
conservatively in cases in which the exclusion of the aortic








— — 49 months
— — 41 months
ovascular ballooning after
days, transposition left
A after 6 months
— 61 months
— — 54 months
AR after 2 days ARDS 22 days
-sided carotid subclavian
pass prior to TEVAR
— 3 months
— Sepsis 36 days
— Sepsis 7 days
AR after 40 days Thoracic infections 89 days
AR after 1 day,
bolectomy and insertion
ant Palmaz stent after 9
onths
— 15 months
— Aortic rupture 2 days
dovascular aneurysm repair (TEVAR). LOS,Hospital length of stay in days;
; ARDS, acute respiratory distress syndrome.
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open AEF repair is a left thoracotomy, followed by aortic
replacement with a prosthetic or cryopreserved homograft,
or an extra-anatomic bypass in case of severe mediastinal
sepsis.5,19 Open thoracic surgery for AEF is, however,
associated with a high operative mortality, which is usually
caused by exsanguination of the patient.3-5 Precise mortal-
ity rates of classic surgery are missing in the literature, due
to the rare occurrence of AEF.
TEVAR is less invasive than open thoracic surgery and
allows prompt exclusion of thoracic aortic fistulas and
control of hemorrhage. No patients died of exsanguination
during TEVAR in our series. However, the follow-up out-
comes after TEVAR were poor. Many patients in our
evaluation developed infectious complications or recurrent
bleeding within the first 3 months after the initial endovas-
cular procedure, which reasonably leaded to death in 5
cases (45%). Endovascular treatment of ABF or AEF alone
does not allow debridement of the potentially contami-
nated thoracic cavity. Additionally, the fistula is not re-
paired and a connection between the lungs or esophagus
with the endograft, the thoracic aorta, and the thoracic
cavity is maintained. This results in continued exposure to
contaminated contents of the esophagus or lungs and high
risk of serious infections. Therefore, additional surgical
repair of the fistula, which may include debridement of the
thoracic cavity, supported by broad-spectrum antibiotic
therapy for at least several months, most likely will improve
outcomes after successful endovascular treatment.
In the literature, numerous cases of endovascular man-
agement of ABF6-8,20-22 and AEF9-11,23-25 have been re-
ported, some with a fatal outcome.22-24 Antibiotic therapy
was frequently prescribed,6,8,10,11,20,22,24,25 additional
open surgical repair was performed in several cases,6,9,11,25
Fig. Survival after TEVAR for aortobronchial fistula (ABF) and
aortoesophageal fistula (AEF) (N  11). This Fig depicts the
survival after thoracic endovascular aneurysm repair (TEVAR) for
ABF and AEF. No deaths occurred after 3 months. Median
follow-up of surviving patients was 45 months (range, 3 to 61
months; interquartile range, 45 months).and sometimes no additional therapy was offered.21,23 Sincecase reports often represent exceptional single cases, it is
difficult to draw valid conclusions regarding the applicability
of endovascular management of ABF and AEF on the basis of
these reports. Larger cases series of TEVAR for ABF demon-
strated a mortality between 0% to 25% at 3 years after the
endovascular procedure.17,26Our results are inconsistentwith
these reports. We have several hypotheses for the inferior
outcome in our series. A possible explanation for the different
outcome is the indication for TEVAR. In theWheatley et al17
and Bockler et al26 series, endovascular management was
preferred in patients with ABF because of co-morbid diseases
and previous thoracotomy.17,26 In our series, TEVAR was
indicated because of emergency treatment in all patients. This
difference could have affected our results.
Another substantial differencewith these previous series is
that we also evaluated outcomes of 4 patients with AEF and 1
patient with combined ABF and AEF, besides 6 patients with
ABF.Deaths in our series included the patient with combined
ABF and AEF and 3 out of 4 patients with AEF; only 1 of 6
patients with ABF expired. It appears that patients with AEF
have a worse outcome after TEVAR compared to patients
with ABF, although strong conclusions cannot be made due
to the small sample size of this series.
Differences in outcomes after TEVAR between ABF
and AEF have not been described previously in the litera-
ture. In this series, 3 out of 4 patients with AEF were
admitted with hemorrhagic shock (Table I), while only 1 of
6 patients with ABF suffered from shock. Hemorrhagic
shock is generally accepted as a risk factor for mortality and
the association of AEF and shock may have led to poorer
outcomes in this series. Two of 3 patients with AEF and
shock expired; death was, however, caused by infectious
complications instead of exsanguination. ABF and AEF are
often associated with infections due to the presence of open
air and esophageal contents in the chest. Exposure to
esophageal contents is possiblymore virulent than exposure
to the open air as well, resulting in increased risks of
infective complications after TEVAR for AEF compared to
ABF.
Although no additional thoracic surgical procedures
were performed in case of ABF, 3 out of 4 patients with
AEF received additional esophageal surgical repair; 1 pa-
tient within a few days after TEVAR and the remaining 2
patients underwent delayed repair after more than 2 weeks
(Table II). The patient, in whom esophageal surgery was
performed a few days after the initial endovascular proce-
dure, was the only patient with AEFwho did not expire; the
remaining patients died of infectious complications (Table
III). This finding suggests a more aggressive surgical ap-
proach of AEF, shortly after initial stabilization by TEVAR.
Topel et al19 recently published promising results of a
combined approach for management of AEF. They used
TEVAR as a bridging procedure in the acute setting, which
was followed by in situ repair with cryopreserved ho-
mografts and long-term antibiotic therapy. This combined
approach could be a valuable option for emergency cases of
AEF, and possibly a more aggressive surgical strategy after
JOURNAL OF VASCULAR SURGERY
November 20091004 Carpenterinitial TEVAR could have prevented some lethal complica-
tions in our series.
CONCLUSION
Endovascular management of emergency cases of ABF
and AEF is associated with poor results. Patients with AEF
treated with TEVAR appear to have an inferior outcome
compared to patients with ABF. TEVAR does prevent
immediate exsanguination in patients admitted with AEF
and ABF but after initial deployment of the endograft and
control of the hemodynamic status, most patients, in par-
ticular those with AEF, are at risk for infectious complica-
tions. Early esophageal repair appears to improve the sur-
vival in case of AEF. Therefore, TEVAR may serve as a
bridge to surgery in emergency cases of AEF with subse-
quent definitive open operative repair of the esophageal
defect as soon as possible. In patients with ABF, additional
open surgery may not be necessary after the endovascular
procedure.
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Mercifully, fistulous communications between the aorta and exsanguination, or be prolonged due to sepsis. The former threat isremedied by prompt treatment of the defect in the aorta, the latter
